Get started
Author

Julia Lynne Glade Bender

OpenAlex ID: A5137094490
Phase II trial of olaparib and ceralasertib in patients with recurrent osteosarcoma: Lung-only resectable cohort efficacy and correlative biomarker results.
2026 · Suzanne J. Forrest, Amanda Marinoff, et al. · Journal of Clinical Oncology · 1
A phase 1b study of tegavivint, a TBL1 inhibitor, with gemcitabine in patients with relapsed or refractory osteosarcoma (TIGER).
2026 · Thomas Cash, Rahul Aras, et al. · Journal of Clinical Oncology
PDF
A phase 1b study of xaluritamig (a STEAP1 x CD3 T-cell engager) in pediatric, adolescent, and adult patients with relapsed/refractory (R/R) Ewing sarcoma.
2026 · Emily K. Slotkin, Leo Mascarenhas, et al. · Journal of Clinical Oncology
Safety and feasibility of cabozantinib (CABO) in combination with cisplatin, doxorubicin, and high-dose methotrexate (MAP) in patients with newly diagnosed high-risk osteosarcoma (OS).
2026 · Michael W. Bishop, Natalie J. DelRocco, et al. · Journal of Clinical Oncology
PDF
Safety and pharmacokinetics (PK) of lurbinectedin (lurbi) in pediatric patients (pts) with relapsed/refractory (R/R) solid tumors and preliminary antitumor activity in pediatric and young adult pts with R/R Ewing sarcoma (EwS): Results from a phase 1 study.
2026 · Julia Lynne Glade Bender, Joseph Gerald Pressey, et al. · Journal of Clinical Oncology
Works count: 5
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type